Selskabets formål er at udvikle og kommercialisere medicinske lægemidler samt anden virksomhed, der står i forbindelse hermed.
| Year | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | -3.4 mio. | -5.4 mio. | 2.8 mio. | 2.1 mio. | 17 | |
CVR: 40804307
Secondary names: Gebamo ApS, Twelve Bio ApS
Previous names: GEBAMO ApS, Twelve Bio ApS
Compared to 994 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Anders Anton Maier joined the board
Magnus Glissmann Bojer-Larsen joined as director
Stefano Stella left as director
Companies in the same industry and area
companydata.dk